RGNX
REGENXBIO Inc. Healthcare Biotechnology
3/12
Innovation Score
Red Flags (1)
SBC_HIGH (64% of revenue)
Patent Activity
2/3
6 patents found
FUZZY
Cash Runway
0/3
8 months of cash remaining based on current burn rate.
Cash on hand: $150.5M
Cash on hand: $150.5M
Revenue Trajectory
0/3
Revenue: $87.8M
YoY Growth: -92.8%
YoY Growth: -92.8%
Management Quality
1/3
Insider ownership: 16.7%
SBC/Revenue: 64.0%
No reverse splits detected
SBC/Revenue: 64.0%
No reverse splits detected
Key Metrics
Market Cap
$295.7M
Revenue
$87.8M
Revenue Growth (YoY)
-92.8%
Cash on Hand
$150.5M
Cash Runway
8 months
Shares Outstanding
51.7M
Insider Ownership
16.7%
SBC / Revenue
64.0%
Sector / Industry
Healthcare / Biotechnology
Patents (6)
Match type: FUZZY — company name matched partially; verify assignee
- Anion exchange chromatography for recombinant AAV production
- Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)
- Treatment of mucopolysaccharidosis IVA
- Methods to treat mucopolysaccharidosis type II or deficiency in iduronate-2-sulfatase using a recombinant adeno-associated virus (AAV) vector encoding iduronate-2-sulfatase
- Scalable clarification process for recombinant AAV production
7-Step Risk Assessment
How RGNX maps to our micro cap methodology:
- Innovation Signal 6 patents identified. This suggests the company is investing in defensible IP.
- Cash Runway Check 8 months of runway. Short runway increases dilution risk — watch for capital raises.
- Revenue Trajectory -92.8% YoY growth on $87.8M revenue. Revenue declining — investigate whether this is temporary or structural.
- Management Alignment Insiders hold 16.7% of shares. SBC is 64.0% of revenue.
- Competitive Moat Review the company's 10-K for barriers to entry: patents, network effects, switching costs, regulatory approvals. This step requires manual research.
- Catalyst Identification Look for upcoming catalysts: FDA decisions, contract wins, product launches, partnerships. Check recent 8-K filings and earnings transcripts.
- Position Sizing Micro caps carry outsized risk. Consider position sizing relative to conviction level and portfolio concentration. This is a $295.7M company.
Financial Detail
Free Cash Flow
$-139.0M
FCF Yield
-47.0%
Return on Equity
-196.4%
Debt / Equity
1178.2%
Gross Margin
-196.6%
Profit Margin
N/A
Operating Margin
-1304.0%
Price / Book
14.02
Current Ratio
2.62
Dividend Yield
None
Share Count Change (YoY)
N/A
Share Count Change (3yr)
N/A
Free Cash Flow Trend
Insufficient Data
Consecutive Years FCF Positive
0
Disclaimer: This is an automated screening tool, not investment advice. Micro cap stocks are inherently risky with low liquidity and high volatility. The innovation score is based on publicly available data and may not reflect the full picture. Steps 5-7 of the methodology require your own research. See our full disclaimer.
Last screened: 2026-05-16